NCT06133088View on ClinicalTrials.gov

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

August 31, 2025

Conditions

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

Interventions

DRUG

dalpiciclib; fluvestrant; compound gossypol acetate tablets

"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."

Trial Locations (1)

310000

RECRUITING

zhejiangCH, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER